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Plasma proteome analysis in HTLV-1-associated
myelopathy/tropical spastic paraparesis
Paul DW Kirk1,7†, Aviva Witkover2†, Alan Courtney3, Alexandra M Lewin4, Robin Wait5, Michael PH Stumpf1,
Sylvia Richardson4, Graham P Taylor6 and Charles RM Bangham2*
Abstract
Background: Human T lymphotropic virus Type 1 (HTLV-1) causes a chronic inflammatory disease of the central
nervous system known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM) which resembles
chronic spinal forms of multiple sclerosis (MS). The pathogenesis of HAM remains uncertain. To aid in the
differential diagnosis of HAM and to identify pathogenetic mechanisms, we analysed the plasma proteome in
asymptomatic HTLV-1 carriers (ACs), patients with HAM, uninfected controls, and patients with MS. We used
surface-enhanced laser desorption-ionization (SELDI) mass spectrometry to analyse the plasma proteome in 68
HTLV-1-infected individuals (in two non-overlapping sets, each comprising 17 patients with HAM and 17 ACs), 16
uninfected controls, and 11 patients with secondary progressive MS. Candidate biomarkers were identified by
tandem Q-TOF mass spectrometry.
Results: The concentrations of three plasma proteins - high [b2-microglobulin], high [Calgranulin B], and low
[apolipoprotein A2] - were specifically associated with HAM, independently of proviral load. The plasma [b2-
microglobulin] was positively correlated with disease severity.
Conclusions: The results indicate that monocytes are activated by contact with activated endothelium in HAM.
Using b2-microglobulin and Calgranulin B alone we derive a diagnostic algorithm that correctly classified the
disease status (presence or absence of HAM) in 81% of HTLV-1-infected subjects in the cohort.
Background
Human T lymphotropic virus Type 1 (HTLV-1) persists
lifelong in the host and is associated with two distinct
types of disease: a range of chronic inflammatory diseases,
of which the most commonly recognized is HTLV-1-asso-
ciated myelopathy/tropic spastic paraparesis (HAM/TSP,
abbreviated hereafter as HAM), and an aggressive T cell
malignancy known as adult T cell leukaemia/lymphoma
(ATLL). The cumulative lifetime risk of HAM ranges
between 0.1% and 3% of infected individuals; the cumula-
tive lifetime risk of ATLL ranges from 1% to 5%.
The strongest correlate of the risk of HTLV-1-asso-
ciated inflammatory diseases such as HAM is the pro-
viral load (PVL), i.e. the percentage of peripheral blood
mononuclear cells (PBMCs) that carry the provirus
[1,2]. The PVL remains approximately constant within
each infected individual, but differs among individuals
by over 1000 times. However, the range of PVL overlaps
extensively between patients with HAM and asympto-
matic carriers: although a PVL > 1% PBMCs is strongly
associated with HAM, 50% of asymptomatic carriers
also have a PVL > 1%, which reduces the value of this
measure in the clinical diagosis of HAM. Furthermore,
other clinical manifestions of HTLV-1 are less well-
defined, and it is difficult to identify in a given case
whether HTLV-1 infection is co-incidental or causative.
There is therefore an urgent need for additional tools to
aid in the diagnosis of HTLV-1-associated disease both
clinically and epidemiologically.
The mechanisms of pathogenesis of the HTLV-1-asso-
ciated inflammatory diseases such as HAM remain
uncertain. To date, most virological and immunological
markers of HAM correlate with proviral load, but do
not differ between patients with HAM and asympto-
matic carriers at a given PVL. Few factors have been
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identified that differ systematically between asympto-
matic carriers and patients with HAM at a given pro-
viral load: the frequency of certain lymphocyte subsets
(HTLV-1-specific CD4+ T cells [3,4]; FoxP3+ CD4+ T
cells [5]; natural killer (NK) cells [6] and NKT cells [7]);
the level of expression of HTLV-1 genes in fresh
PBMCs [5,8-10]; and the pattern of integration of the
HTLV-1 provirus in the host cell genome [11]. How-
ever, none of these parameters is useful in the differen-
tial diagnosis of HAM from other causes of spastic
paraparesis, and these parameters give only indirect sug-
gestions as to the pathogenesis of the inflammatory con-
ditions such as HAM.
The aim of the present study was to identify plasma pro-
teins whose concentration is associated with HAM or cor-
related with proviral load, to help in the differential
diagnosis of HAM and to provide further clues as to the
mechanism of pathogenesis of the inflammatory disease. In
a two-stage case-control study, we used surface-enhanced
laser desorption ionization time-of-flight mass spectrometry
(SELDI-TOF-MS; abbreviated here as SELDI) to identify
plasma protein biomarkers that distinguished patients with
HAM from both asymptomatic HTLV-1 carriers and
patients with progressive multiple sclerosis, which closely
resembles HAM clinically. Three biomarkers were identi-
fied by tandem mass spectrometry. We derive algorithms
to estimate the utility of these biomarkers in the differential
diagnosis of HAM, and discuss their possible significance
in the pathogenesis of the disease.
Results
Univariate analysis revealed 4 biomarkers of HAM
Four successive pairwise comparisons were carried out:
HAM vs. AC; AC vs. U; HAM vs. U; and (HAM and
AC) vs. U. The results in Table 1 show the molecular
weights of the peaks identified in each comparison for
the original and verification data sets respectively. The
p-values returned by the Biomarker Wizard software
were converted into q-values, which estimate the false
discovery rate [12] and account for multiple testing.
In the comparison of HAM vs. AC, four peaks remained
statistically significant in both the original and verification
data sets after multiple testing correction: the 11.7 kDa,
11.9 kDa, 13.3 kDa and 14.7 kDa peaks. As illustrated in
Figure 1, the intensities of all four peaks were typically
higher in the HAM group. The intensities of all four peaks
in HAM patients also differed significantly from those in
uninfected controls (Table 1; Additional File 1, S4).
The plasma proteomic profile differed between HAM and
multiple sclerosis
The samples from patients with HAM were compared
with the samples from patients with secondary progres-
sive MS. The results are shown in Table 2.
Several peaks differed in intensity between the HAM
and MS spectra (Table 2). The first four of these peaks
(10.1 kDa, 3.8 kDa, 7.7 kDa and 9.2 kDa) were detected
consistently only amongst the MS spectra; in the HAM
spectra, their intensities fell below the noise level. For
all but 2 of the peaks (9.4 kDa and 14.0 kDa), the mean
intensity was higher in samples from patients with MS.
Protein peak intensities were uncorrelated with proviral
load
After correction for multiple testing, we found no peaks
whose normalized log intensities remained significantly
correlated with log(proviral load) in either the original
or verification sets.
SELDI data enabled HAM and AC to be distinguished with
79% cross-validation success rate
We aimed to identify protein peaks that discriminated
between: (1) HAM and AC; and (2) HAM and MS.
1. HAM vs. AC. Three peaks (13.3 kDa, 11.7 kDa and
17.6 kDa) gave the lowest mean cross-validation (CV)
misclassification rate (20.7%). The mean CV misclassifi-
cation rate for the 11.7 kDa peak alone was 22.8%, and
for 11.7 kDa and 13.3 kDa together was 21.4%.
2. HAM vs. MS. The 10.1 kDa peak alone gave the
lowest mean CV misclassification rate of 6.6%, and
further selections did not improve predictive
performance.
The separation between the subject groups provided
by the two most stably selected peaks in each of these
cases is shown in Figure 2.
Proviral load provided additional discriminatory
information
Repeating the multivariate analysis of the HAM and AC
classes including log(proviral load) as a predictor, we
identified four parameters as significant discriminators:
proviral load and the 13.3 kDa, 11.7 kDa and 11.9 kDa
peaks. These four parameters combined gave a mean
misclassification rate of 14.6%; the log(proviral load)
alone provided a mean CV misclassification rate of 21.0%.
A simple classification rule using the SELDI data
We constructed a classifier to discriminate between
HAM and AC using only the 11.7 kDa and 13.3 kDa
peaks, since these peaks were selected consistently in all
analyses. For simplicity, we categorized the observed
intensity values for each of these two peaks as either
‘normal’ or ‘abnormal’. ‘Normal’ intensity measurements
(Figure 2a, shaded region) were defined as those within
2 standard deviations of the mean amongst the unin-
fected controls (intensity = 3.2 ± 1.1 for the 11.7 kDa
peak; 1.2 ± 1.2 for 13.3 kDa). From a logistic regression
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Table 1 Protein peaks whose intensity differed significantly (FDR level 0.05) between the two respective subject
groups.
Original data set
HAM vs. AC AC vs. U(*) HAM vs. U (HAM & AC) vs. U
MW (kDa) q-value MW (kDa) q-value MW (kDa) q-value MW (kDa) q-value
11.7 5.6E-04 11.7 1.0E-04 11.7 3.7E-02
11.9 9.4E-04 11.9 2.7E-04 11.9 4.4E-02
13.3 1.5E-03 13.3 3.9E-04 12.7 4.4E-02
14.7 1.9E-02 14.7 1.5E-03 13.3 4.4E-02
17.6 2.6E-02 25.4 4.5E-02 14.7 4.4E-02
Verification data set
HAM vs. AC AC vs. U HAM vs. U (HAM & AC) vs. U
MW (kDa) q-value MW (kDa) q-value MW (kDa) q-value MW (kDa) q-value
14.7 2.1E-02 13.8 6.2E-04 13.8 6.7E-04 13.8 3.4E-05
13.3 2.1E-02 6.9 5.6E-03 11.7 6.7E-04 6.9 1.3E-03
11.7 2.1E-02 9.7 1.5E-02 14.7 1.6E-03 14.0 7.2E-03
11.9 2.1E-02 14.0 3.6E-02 17.4 4.0E-03 11.7 9.9E-03
8.8 2.1E-02 8.6 3.6E-02 79.1 4.0E-03 8.6 9.9E-03
17.6 4.0E-03 13.9 1.3E-02
6.9 4.0E-03 17.4 1.3E-02
39.7 4.0E-03 17.6 1.3E-02
13.3 5.3E-03 12.8 1.7E-02
14.0 7.0E-03 79.1 1.7E-02
17.4 3.3E-02
Results are ordered by q-value; for brevity only the first ten results with q-value < 0.05 are shown (complete tables are provided in Additional file 1, S4). Peaks
that reached significance (q < 0.05) in both original and verification sets are indicated in bold. (*) No peaks differed significantly between the AC and U groups in
the original data set.
Figure 1 Heatmap representation of intensities of the 11.7 kDa, 11.9 kDa, 13.3 kDa and 14.7 kDa peaks. a) original data set; b)
verification data set. Each row corresponds to a single subject; each column denotes a different protein peak. The colour depicts the log (peak
intensity), after subtracting the median for each peak.
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analysis of the resulting categorical data (see Additional
file 1, S5), we derived the following rule:
“If the intensity of either the 11.7 kDa or the 13.3 kDa
peak (or both) is abnormal, then classify as HAM”.
This rule correctly classified 55/68 = 81% of seropositive
subjects in the ‘combined’ data set; this performance level
may be overestimated, since the same data were used both
to devise and assess the rule. Of the 13 misclassified indivi-
duals, 2 were ACs misclassified as HAM (i.e. false positive
diagnosis of HAM), corresponding to a false positive rate
of 5.9% and a false negative rate of 32.4%.
Protein Identification
Because of their consistent significance in the statistical
analysis, we wished to identify the proteins that consti-
tuted the 11.7 kDa and 13.3 kDa peaks. We also
attempted identification of the 17.4 kDa and 14.7 kDa
peaks (see Table 1).
Q-TOF mass spectrometry identified the 17.4 kDa
protein as apolipoprotein A-II (ApoA-II). The species
present was presumably the S-S linked homodimer [13],
whose calculated mass is 17.416 kDa, since the theoreti-
cal mass of its monomer (residues 24-100) is 8.708 kDa.
This identification was confirmed by adding dithiothrei-
tol (DTT) to the eluate containing the 17.4 kDa protein
and repeating the SELDI analysis (Figure 3). Details of
peptide fragments detected in the Q-TOF analysis are
available on request.
Q-TOF analysis also identified the 11.7 kDa and 13.3
kDa protein eluates as b2-microglobulin (calculated
mass 11.731 kDa) and Calgranulin B (Protein S100-A9)
(calculated mass 13.224 kDa).
Purification of the 14.7 kDa protein by anionic fractio-
nation and 1D-SDS-PAGE failed to resolve the peaks
into separate gel bands. Three consistent peaks were
detected by SELDI analysis. Q-TOF-MS analysis
revealed three potential identities: transthyretin (calcu-
lated mass = 13761.4 Da); serum amyloid A-4 (SAA-4)
(calculated mass = 12863.28 Da; glycosylation may
increase the mass in vivo); and lysozyme.
Figure 2 Separation of (a) HAM and AC and (b) HAM and MS samples using the two most stably selected peaks. In (a), the enclosed
shaded region indicates a “normal range” of intensities for the two peaks, as determined from the uninfected controls.
Table 2 Peaks that differed between HAM and MS
samples, in descending order of statistical significance.
HAM vs. MS
MW (kDa) q-value
10.1 2.32E-04
3.8 2.32E-04
7.7 2.32E-04
9.2 2.32E-04
10.3 3.28E-04
37.4 3.28E-04
9.4 4.56E-04
10.8 4.78E-03
14.0 4.78E-03
60.4 4.78E-03
Only the first ten results are shown; complete data are provided in Additional
file 1, S4.
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Confirmation of identity of b2-microglobulin
The plasma concentration of b2-microglobulin was
measured in the subjects in the original sample set (17
patients with HAM, 17 ACs, 16 uninfected subjects) by
rate nephelometry. The area under the 11.7 kDa peak
was significantly correlated (Spearman rank correla-
tion, 2-tailed) with the b2-microglobulin concentration
in both the uninfected individuals (p = 0.023) and the
asymptomatic carriers (p = 0.006); the correlation was
suggestive in the patients with HAM (p = 0.09). The
statistical significance of the correlation in the three
subject groups combined was p = 0.0009, by Fisher’s
method of combining probabilities [14]. We conclude
that the 11.7 kDa peak was formed by b2-
microglobulin.
Correlation between plasma b2-microglobulin
concentration and disability in HAM patients
A good objective measure of the disability caused by
HAM is the time taken by the patient to walk 10 m on
a flat, smooth surface. There was a significant positive
correlation between the 10 m timed walk and the
plasma b2-microglobulin concentration (Figure 4).
Discussion
Biomarkers serve three chief purposes: to assist in the
diagnosis of a clinical condition, to follow the progression
of disease and response to treatment, and to give clues as
to the pathogenetic mechanisms of the disease in question.
Figure 4 In patients with HAM, the plasma concentration of
b2-microglobulin (measured by rate nephelometry) was
positively correlated with the time taken by the patient to
walk 10 m. Of the 5 patients with the highest plasma [b2-
microglobulin], four were confined to a wheelchair (top right of
figure, unfilled symbols; the two symbols to the right of the//mark
represent values of 2.1 and 6.1 mg. L-1 respectively).
Figure 3 Reduction of the putative ApoA-II homodimer (17.4 kDa) using DTT. DTT was added to the passive eluate containing the 17.4
kDa protein and analysed on NP20 chips using SELDI-TOF-MS. (A) spectrum from eluate in absence of DTT; (B) spectrum from the same eluate
after addition of DTT: the height of the 17.4 kDa peak was diminished and the peak at 8.7 kDa was correspondingly increased.
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We identified two plasma proteins whose abundance
in HTLV-1-infected individuals was significantly and
independently associated with the presence of HAM:
b2-microglobulin and Calgranulin B. Moreover, the
plasma b2-microglobulin concentration was significantly
correlated with the degree of disability resulting from
HAM as measure by the 10 m timed walk (Figure 4).
Two further peaks (11.9 kDa and 14.7 kDa) had intensi-
ties that were strongly correlated with the 11.7 kDa (b2-
microglobulin) and 13.3 kDa (Calgranulin B) peaks
respectively. However, inclusion of these peaks did not
add significantly to the discrimination between asympto-
matic HTLV-1 carriers and patients with HAM. A logis-
tic regression model including the abundance of the two
most strongly associated biomarkers, b2-microglobulin
and Calgranulin B, correctly classified the clinical status
of HTLV-1-infected subjects in the present cohort with
79% accuracy (i.e. CV misclassification rate of 21%). A
17.4 kDa protein peak, identified as Apolipoprotein-AII
(Apo-AII), was also of particular interest as it was more
abundant in asymptomatic carriers than in patients with
HAM.
Two of the identified peaks (b2-microglobulin and
Calgranulin B) discriminated between HAM and MS
patients, with a CV misclassification rate of 25.0%. How-
ever, the best discrimination between patients with
HAM and those with secondary progressive MS was
provided by the protein peak at 10.1 kDa (Figure 2b):
this protein awaits identification.
The serum concentration of b2-microglobulin is in
clinical use as a marker of chronic renal disease, in risk
stratification and as a measure of disease burden in cer-
tain haematological malignancies [15-17], and as a mea-
sure of disease activity and progression in HIV-1 [18]
and HIV-2 infection [19]. In Alzheimer’s disease, Simon-
sen et al. [20] found a lower concentration of b2-micro-
globulin in the cerebrospinal fluid (CSF) in patients
compared with healthy age-matched controls, using
SELDI techniques. In one study of multiple sclerosis, a
higher concentration of b2-microglobulin was found in
CSF in patients with active disease compared with
healthy individuals [21]; however, this finding was not
reproduced in subsequent studies, either in CSF [22,23]
or in the serum b2-microglobulin concentration [23]. In
patients with HAM, as in HIV-1 [18] and HIV-2 infec-
tions [19], it is likely that the high b2-microglobulin
concentration in serum is a result of chronic activation
of large numbers of T cells.
Calgranulin B [24,25] is also known as S100A9 and as
myeloid-related protein 14 (MRP14). Together with the
related protein Calgranulin A (S100A8; MRP8), Calgra-
nulin B forms a heterodimer called Calprotectin, which
plays a central part in calcium ion signalling during
inflammation. Calgranulin B is expressed chiefly in
neutrophils, and in monocytes after activation of protein
kinase C. It is also expressed in some epithelial cells,
but not in fixed tissue macrophages or in lymphocytes.
Contact with activated endothelium induces monocytes
to secrete Calgranulin B (by a microtubule-dependent
mechanism), but contact with resting endothelium sup-
presses this secretion [26]. The concentration of Calgra-
nulin B in serum (or other fluids such as synovial fluid)
correlates with disease activity in a wide range of
inflammatory conditions, including rheumatoid arthritis
[27], pauciarticular onset juvenile rheumatoid arthritis
[26]; inflammatory bowel disease [28]; chronic airway
inflammation [29]; kidney allograft rejection [30] and
acute appendicitis [31].
The strong association found in this study between
serum Calgranulin B abundance and HAM suggests that
monocytes are activated by contact with activated
endothelium in patients with this disease. However,
macrophages themselves may not contribute to the tis-
sue damage seen in HAM: macrophages are not a pro-
minent feature of the cellular infiltrate in CNS lesions
[32].
Apolipoprotein-AII (Apo-AII) [33] is a major constitu-
ent of high-density lipoproteins (HDL). Castellani et al.
[34] found that overexpression of Apo-AII in transgenic
mice converted HDL to proinflammatory particles
which induced transmigration of monocytes across the
arterial wall, and these authors suggested a role of Apo-
AII in atherosclerosis. Further evidence of an inflamma-
tory role of Apo-AII was found by Thompson et al.
[35], who showed that Apo-AII enhanced the monocyte
response to bacterial lipopolysaccharide. The present
results show that a high peak of Apo-AII was associated
with asymptomatic carrier status. Further work is war-
ranted to investigate the possible contribution of mono-
cytes to the pathogenesis of HAM.
Semmes et al. [36] reported a SELDI analysis of serum
proteins in HTLV-1 infection. These authors compared
the SELDI proteomic profile between patients with
ATLL, patients with HAM, and uninfected control sub-
jects. They found that two serum proteins were overex-
pressed in ATLL: these proteins were identified as
alpha-1-antitrypsin and haptoglobin-2 respectively by
tandem mass spectrometry. The authors concluded that
these two proteins could serve as biomarkers to distin-
guish between ATLL and HAM. However, these authors
did not examine the serum proteome in asymptomatic
HTLV-1 carriers or patients with multiple sclerosis, and
the relationship between the protein peak intensity and
the proviral load of HTLV-1 was not explored.
Conclusions
The biomarkers identified here are potentially of clinical
use, because they were specifically associated with the
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presence of the disease, HAM, and gave additional dis-
criminatory information to that provided by the proviral
load. These biomarkers may therefore serve both in the
differential diagnosis of HAM and in following the dis-
ease activity and response to treatment in individual
patients. The plasma (or serum) concentration of b2-
microglobulin may be of particular clinical utility,
because the assay is readily available in clinical chemis-
try laboratories and because the concentration correlates
with clinical severity (degree of disability). The classifica-
tion rule (”if the intensity of either the 11.7 kDa or the
13.3 kDa peak - or both - is abnormal, then classify as
HAM”) provides a useful basis for further clinical test-
ing. In addition, it will be interesting to investigate these
biomarkers in other diseases that are known or sus-
pected to be caused by HTLV-1, such as polymyositis,
arthritis and uveitis.
Methods
Subjects; plasma samples
Plasma was prepared from EDTA-anticoagulated per-
ipheral venous blood samples donated by a total of 95
subjects, comprising 68 HTLV-1 infected patients (34
patients with HTLV-1 associated myelopathy/tropical
spastic paraparesis (HAM) and 34 asymptomatic
HTLV-1 carriers (ACs)) and 16 ethnically matched
uninfected controls (U) attending clinic at the
National Centre for Human Retrovirology, St Mary’s
Hospital, London. These samples form part of the
Research Tissue Bank (Imperial College London),
approved by the UK National Research Ethics Service
(09/H0606/106). EDTA-anticoagulated peripheral
venous blood samples were also donated by 11
patients with secondary progressive multiple sclerosis
attending Charing Cross Hospital, London. All
patients gave written informed consent. Details of par-
ticipating subjects (age, sex, ethnicity, disease status)
are available on request.
Sample processing
Samples were analysed by SELDI using the CM10 Pro-
teinChip array (Bio-Rad, Hemel Hempstead, UK) with
50 mM sodium acetate buffer (pH4), and sinapinic acid
as the energy-absorbing matrix. Data were collected at
low- and high-mass ranges consecutively, using the
manufacturer’s protocol. The low-mass range was 1-30
kDa (highest mass collected 50 kDa) and the high-mass
range 10-75 kDa (highest mass collected 100 kDa). For
each subject we then combined the data in the optimal
part of each mass range (1 to 10 kDa from the low-
mass range and 10 to 100 kDa from the high-mass
range). See Additional file 1, S1 for details.
Processing of spectral data: Biomarker Wizard
Spectra were processed using the Ciphergen Pro-
teinChip Software (version 3.2.0). Before statistical ana-
lysis with the proprietary software package Biomarker
Wizard (Bio-Rad), spectra were calibrated using four
molecular weight standards and normalized by intensity
(total ion current). The spectra from each experiment
were analysed as either low- or high-mass data, in two
groups (HAM vs AC; AC vs U; HTLV-1+ vs MS). Fol-
lowing the manufacturer’s guidelines, criteria for protein
peak detection were a signal to noise ratio (S/N) of ≥10
and presence of the peak in ≥40% of samples in at least
one subject group. All spectra were inspected visually by
an experienced SELDI operator; no spectra were omitted
from the study.
Experimental design
The study comprised three stages. In stage 1 we ana-
lysed samples from 17 patients with HAM, 17 ACs and
16 Us. In stage 2 we analysed samples from a non-over-
lapping cohort of 17 HAM patients and 17 ACs together
with repeat aliquots of the plasma samples from 14 of
the 16 Us studied in the first set. Finally, samples from
11 patients with MS were analysed together with 12
samples chosen randomly from the 34 patients with
HAM. These three data sets were respectively denoted
the ‘original’, ‘verification’ and ‘MS’ sets.
To derive predictive multivariate models, we pooled
data from the ‘original’ and ‘verification’ sets to create a
‘combined’ data set comprising samples from all 68
HTLV-1-seropositive individuals, after further normali-
zation to minimize bias due to chip-specific effects [37].
Further details are provided in Additional file 1, S2. As
an alternative approach, we trained a predictive model
using the ‘original’ dataset only, and then tested its per-
formance on the ‘verification’ dataset. This method also
yielded good results (see Additional file 1, S8). The
workflow of sample processing and analysis is summar-
ized in Additional file 1, S9.
Univariate Analysis
Association with disease group
For each comparison of interest we identified significant
differences (Mann-Whitney U test) in the distributions
of peak intensities between the two respective subject
groups.
Correlation with proviral load
We tested for a correlation (Kendall’s τ rank correlation
coefficient; exact p-values) between protein peak intensi-
ties and proviral load separated in samples from ACs
and patients with HAM in the original and verification
data sets.
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Multiple testing correction
For all univariate tests, we controlled the false discovery
rate at q = 0.05 [12,38].
Multivariate Analysis
Prediction and peak selection
We used a logistic regression model to describe the
probability of disease outcome. To fit the model to the
data we used a maximum likelihood method incorporat-
ing the lasso penalty [39,40]. A stability selection
approach [41] was used to select the peaks whose selec-
tion was robust to data variability. We selected the opti-
mum number of peaks using a cross-validation
assessment of predictive performance. Further details
are provided in Additional file 1, S3.
Identification of candidate biomarker proteins
To identify the candidate proteins, plasma samples with
a high abundance of the desired protein (i.e. high peak
height on the SELDI spectrum) were selected. HAM
samples were used to identify 11.7 kDa, 13.3 kDa and
14.7 kDa proteins, whereas AC plasma was used to
identify the 17.4 kDa protein. Albumin-depleted plasma
was subjected to successive anionic exchange fractiona-
tion and reverse phase fractionation; and separated by
1D-SDS-PAGE. Proteins at the target molecular weight
were digested with trypsin (either in gel or after passive
elution) and analysed using Q-TOF-MS/MS. All samples
were run in duplicate. See Additional file 1, S6 for
further details.
Protein identification by tandem mass spectrometry
Gel bands were excised and digested with trypsin as
previously described [42]. Samples were analysed by
high performance liquid chromatography coupled to
electrospray ionization tandem mass spectrometry
(HPLC ESI MS/MS using a Waters Q-TOF instrument).
Proteins were identified by correlation of uninterpreted
spectra to the SwissProt database (Release 2010_04)
using Mascot (version 2.2: http://www.matrixscience.
com). MS/MS ion searches specified up to two missed
cleavages per peptide, a precursor mass tolerance of ±
100 ppm and a fragment ion mass tolerance of ± 0.5Da.
Carbamidomethylation of cysteines and methionine oxi-
dation were specified as fixed and variable modifications
respectively.
Q-TOF MS/MS based peptide and protein identifica-
tions were validated using the Protein and Peptide Pro-
phet algorithms, as implemeted in the program Scaffold
version 3.01 [43] (Proteome Software Inc., Portland,
Oregon). Peptide identifications were accepted if they
could be established at greater than 95.0% probability.
Protein identifications were accepted if established at
greater than 99.0% probability and contained at least 2
matched peptides.
Additional material
Additional file 1: Study design, methods and results. Additional file 1
contains further details on the following: study design; sample
processing; chip-specific normalization; prediction and peak selection;
complete significance tables; a simple classification rule using the SELDI
data; differences in detection; protein identification (materials &
methods); prediction using ‘original’ dataset as training set and
‘verification’ as test set; workflow summary; and references.
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